The human trials of India’s indigenous COVAXIN are set to begin in AIIMS-Delhi, Redkar Hospital in Goa and Bhubaneswar’s Institute of Medical Sciences and SUM Hospital.
A phase II human trial of a potential corona vaccine candidate was conducted in China. Initial results have showed that it is safe and induces an immune response, a study published in The Lancet was quoted as saying by PTI. Scientists said the results provide data from a wider group of participants than their earlier phase I trial, including a small sub-group of participants aged over 55 years and older.
The race to develop Coronavirus COVID19 vaccine has become an intriguing one after UK’s Oxford-AstraZeneca, Russia, US-based Moderna, India’s COVAXIN and Zydus Cadila, and Chinese companies including Sinovac made significant progress. Around the world, over 160 potential Coronavirus COVID19 vaccines are at different stages of development. Out of those, as many as 26 vaccines have managed to enter human trials phase.
Oxford-AstraZeneca’s endeavour to develop a potential Coronavirus vaccine has been a ray of hope. On July 20, UK-based medical journal, ‘The Lancet’ published the results of the 1/2 of the Oxford Coronavirus COVID Vaccine trial. The report stated that the potential coronavirus vaccine candidate “safe, well-tolerated and immunogenic.” Oxford-AstraZeneca has already tied up with nine firms across the world. It has also committed to the production of 2 billion doses after the vaccine gets the approval. Serum Institute of India, Pune is one of the nine partners of Oxford-AstraZeneca. There is also a plan to begin clinical trials for the Oxford vaccine in India. Meanwhile, the Serum Institute of India has stated that it would apply for a licence from the Indian regulator DGCI to start clinical trials of the Oxford vaccine next week
The human trials of Indria’s indigenous COVAXIN are set to begin in AIIMS-Delhi, Redkar Hospital in Goa and Bhubaneswar’s Institute of Medical Sciences and SUM Hospital. The clinical trials of the potential vaccine, which is being developed by the Indian Council for Medical Research (ICMR), Bharat Biotech International Limited (BBIL), and National Institute of Virology, Pune, has begun at AIIMS Patna and PGI Rohtak. Clinical trials of the Covaxin will also begin at Medical institutes and hospitals located in Visakhapatnam, Belgaum in Karnataka, Nagpur, Uttar Pradesh’s Gorakhpur and Kanpur, Tamil Nadu’s Kattankulathur, Hyderabad, and Arya Nagar.
Russia has been claiming that the “World’s first Coronavirus COVID vaccine” would be ready by August. According to a Bloomberg report, Russia’s business and political elite have been given access to the experimental potential Coronavirus vaccine. The vaccine, which is being developed by the Gamaleya Research Institute of Epidemiology and Microbiology, has been funded by the state-run Russian Direct Investment Fund. The project is also backed by the Defense Ministry. Last week, a phase 1 trial of the potential vaccine candidate involving military personnel was completed. However, no result has been published. The institute has already begun the next stage of testing with a larger group. However, researchers in Russia have claimed that the potential vaccine candidate is “safe and reliable”.
US-based Moderna is developing a potential Coronavirus vaccine candidate. In fact, Moderna is the first organization to start the human trials of the vaccine candidate on March 16, 5 days after WHO had termed Coronavirus as “pandemic”. The initial results have shown early promise. The firm will begin Phase 3 trials with 30,000 on July 27.
WHO has recognized that over 20 potential coronavirus vaccine candidates are at the human trial stages and almost half of those are being developed by Chinese firms. One such is Sinovac. WHO has said that along with Oxford, “good news” in results shown by a Chinese firm. Chinese pharmaceutical firm Sinovac is the only third in the world to enter Phase 3 trials. The large scale testing is set to begin in six states in Brazil. Sinovac has also received a nod for Phase 3 trials in Bangladesh.